Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Bulozna oralna erupcija uzrokovana azitomicinom (CROSBI ID 179332)

Prilog u časopisu | stručni rad

Lončar, Božana ; Mravak-Stipetić, Marinka ; Skerlev, Mihael ; Baričević, Marinka ; Makar Aušperger, Ksenija Bullous oral eruptions caused by azithromycin / Bulozna oralna erupcija uzrokovana azitomicinom // Acta stomatologica Croatica, 45 (2011), 2; 120-124

Podaci o odgovornosti

Lončar, Božana ; Mravak-Stipetić, Marinka ; Skerlev, Mihael ; Baričević, Marinka ; Makar Aušperger, Ksenija

hrvatski

Bulozna oralna erupcija uzrokovana azitomicinom

Macrolides are considered the safest group of antibiotics, with a very low prevalence of allergic reactions (0.4-3%). We present a case report of a young patient who developed bullous eruption on buccal mucosa and lips after ingestion of the third dose of azithromycin. After taking steroid therapy the lesions started to regress, but on the fourth day a new bullous eruption appeared on labial mucosa with lower intensity. This could be explained by the fact that azithromycin has a long plasma half-life and is detectable in neutrophil lysates 28 days after the last dose, which may be related to a higher risk of adverse effects. According to our knowledge and from the available literature. This is the first described case of oral eruption after azithromycin treatment. In spite of the fact that azithromycin remains one of the best tolerated macrolides, potentially severe adverse reactions may sometimes occur.

oralna sluznica; bulozna erupcija; azitromicin; oralna reakcija na lijek

nije evidentirano

engleski

Bullous oral eruptions caused by azithromycin

Macrolides are considered the safest group of antibiotics, with a very low prevalence of allergic reactions (0.4-3%). We present a case report of a young patient who developed bullous eruption on buccal mucosa and lips after ingestion of the third dose of azithromycin. After taking steroid therapy the lesions started to regress, but on the fourth day a new bullous eruption appeared on labial mucosa with lower intensity. This could be explained by the fact that azithromycin has a long plasma half-life and is detectable in neutrophil lysates 28 days after the last dose, which may be related to a higher risk of adverse effects. According to our knowledge and from the available literature. This is the first described case of oral eruption after azithromycin treatment. In spite of the fact that azithromycin remains one of the best tolerated macrolides, potentially severe adverse reactions may sometimes occur.

oral mucosa; oral bullous eruption; azitromycin; oral adverse drug reaction

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

45 (2)

2011.

120-124

objavljeno

0001-7019

Povezanost rada

Dentalna medicina

Poveznice
Indeksiranost